A Phase I/IIa Rollover Study of the Whole-Cell Vaccine BriaVax™ in Metastatic or Locally Recurrent Breast Cancer Patients in Combination With Ipilimumab or Pembrolizumab

Trial Profile

A Phase I/IIa Rollover Study of the Whole-Cell Vaccine BriaVax™ in Metastatic or Locally Recurrent Breast Cancer Patients in Combination With Ipilimumab or Pembrolizumab

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Pembrolizumab (Primary) ; SV-BR-1-GM breast cancer vaccine BriaCell Therapeutics (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors BriaCell Therapeutics Corp
  • Most Recent Events

    • 06 Nov 2017 According to a BriaCell Therapeutics media release, the three US sites are 1) Santa Rosa, St. Joseph Health-Sonoma County, CA, 2) Florida Cancer Care, Plantation, FL, and 3) The Everett Clinic and Providence Regional Medical Center, Everett, WA. Additional sites are planned to open in coming months
    • 06 Nov 2017 According to a BriaCell Therapeutics media release, patients enrollment initiate in Q12018.
    • 30 Oct 2017 According to a BriaCell Therapeutics media release, FDA has approved roll-over combination study with checkpoint inhibitors (ipilimumab or pembrolizumab)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top